The Appraisal Committee was due to meet on 16 February 2016 to discuss the use of lenalidomide for treating relapsed or refractory mantle cell lymphoma. The company has indicated that they will not be making a submission for this appraisal. Consequently, NICE will suspend the appraisal whilst we consider the next steps.
 
Status Suspended
Process STA
Referral date 01 March 2015

Project Team

Project lead Bijal Joshi

Timeline

Key events during the development of the guidance:

Date Update
06 November 2015 The Appraisal Committee was due to meet on 16 February 2016 to discuss the use of lenalidomide for treating relapsed or refractory mantle cell lymphoma. The company has indicated that they will not be making a submission for this appraisal. Consequently, NICE will suspend the appraisal whilst we consider the next steps.
06 November 2015 Suspended, The Appraisal Committee was due to meet on 16 February 2016 to discuss the use of lenalidomide for treating relapsed or refractory mantle cell lymphoma. The company has indicated that they will not be making a submission for this appraisal. Consequently, NICE will suspend the appraisal whilst we consider the next steps.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance